![Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. - Abstract - Europe PMC Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6067940/bin/onco12425-fig-0002.jpg)
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. - Abstract - Europe PMC
![PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health](https://images.everydayhealth.com/images/lynparza-lengthens-survival-in-some-relapsed-ovarian-cancer-patients-722x406.jpg)
PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health
![AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial | Fierce Pharma AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/2017-03/LynparzaOlaparib.jpg?VersionId=z8gdnLiFrMhtx_Oshf1NvZPVu6EzlG8u)